Active Ingredient History

  • Now
Iniparib was a drug candidate for cancer treatment. It was originally believed to act as an irreversible inhibitor of PARP1 and possibly other enzymes through covalent modification, but its effects against PARP were later disproven. It underwent clinical trials for treatment of some types of breast cancer, but was discontinued after disappointing phase III clinical trials.   Wikipedia

  • SMILES: NC(=O)c1ccc(I)c(c1)[N+](=O)[O-]
  • Mol. Mass: 292.03
  • ALogP: 1.3
  • ChEMBL Molecule:
More Chemistry
4-iodo-3-nitrobenzamide | bsi201 | bsi 201 | bsi-201 | iniparib


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue